Mirati Therapeutics, Inc.
(NASDAQ : MRTX)

( )
MRTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.93%158.000.0%$686.24m
AMGNAmgen, Inc. -0.25%250.581.5%$604.45m
GILDGilead Sciences, Inc. -0.47%66.021.0%$437.82m
VRTXVertex Pharmaceuticals, Inc. -1.24%299.231.9%$414.73m
REGNRegeneron Pharmaceuticals, Inc. -1.91%636.342.6%$364.61m
ILMNIllumina, Inc. -3.10%213.023.3%$317.77m
SNSSSunesis Pharmaceuticals, Inc. -0.98%4.060.7%$283.81m
NVAXNovavax, Inc. -8.19%39.3775.7%$258.88m
BIIBBiogen, Inc. -0.94%217.581.8%$192.12m
BNTXBioNTech SE -5.19%152.040.0%$149.19m
GOVXGeoVax Labs, Inc. 0.44%2.260.0%$119.92m
BMRNBioMarin Pharmaceutical, Inc. -0.20%94.844.2%$100.34m
SAVACassava Sciences, Inc. 27.26%25.720.0%$95.08m
CRSPCRISPR Therapeutics AG -5.42%71.740.6%$92.05m
PACBPacific Biosciences of California, Inc. -4.88%7.616.2%$87.70m

Company Profile

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.